Companies Dominating the Necrotizing Gingivostomatitis Treatment Landscape
- Novartis International AG
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Teva Pharmaceutical Industries Ltd.
- Mylan N.V.
- Sanofi S.A.
- GlaxoSmithKline plc
- Merck & Co., Inc.
- Otsuka Pharmaceutical Co., Ltd.
- Abbott Laboratories
- Eli Lilly and Company
- Hindustan Antibiotics Limited
- Aviro Health L.P.
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
In the year 2025, the industry size of necrotizing gingivostomatitis treatment is evaluated at USD 18.94 million.
The necrotizing gingivostomatitis treatment market size was valued at USD 17.06 million in 2024 and is set to exceed USD 39.64 million by 2037, expanding at over 6.7% CAGR during the forecast period i.e., between 2025-2037. Increasing incidences of necrotizing gingivostomatitis and the rising use of public toilets will boost the market growth.
North America industry is expected to hold largest revenue share of 39% by 2037, attributed to high prevalence of lifestyle diseases, caused by inactive routines, busy lifestyles, and unhealthy eating habits.
The major players in the market are Novartis International AG, Teva Pharmaceutical Industries Ltd., Mylan N.V., Sanofi S.A., GlaxoSmithKline plc, Merck & Co., Inc., Otsuka Pharmaceutical Co., Ltd., Abbott Laboratories, Eli Lilly and Company, Hindustan Antibiotics Limited, Aviro Health L.P.
